Zoledronic acid (Zoledronate)

別名：ZA, CGP-4244, GP42446A, ZOL 446

製品コード：S1314 純度：99.80%

Zoledronic acid (Zoledronate), a potent osteoclast inhibitor, induces apoptosis in osteoclasts by inhibiting enzymes of the mevalonate pathway and preventing the isoprenylation of small GTP-binding proteins such as Ras and Rho. Zoledronic acid (ZA) also induces autophagy.

CAS No. 118072-93-8

サイズ	価格(税別)	在庫状況
25mg	JPY 22000	国内在庫あり
100mg	JPY 40500	国内在庫あり
1g	JPY 100500	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（52）

製品安全説明書

現在のバッチを見る：純度： 99.80%

99.80

Zoledronic acid (Zoledronate)関連製品

関連ターゲット	H-ras N-ras K-ras Ral	もっと見る
関連製品	ARS-1620 Salirasib Adagrasib (MRTX849) ARS-853 BI-3406 BI-3406 MRTX1133 BAY-293 K-Ras(G12C) inhibitor 12 RBC8 Kobe0065 KRpep-2d BQU57 BI-2852 CID-1067700 (ML282)	もっと見る
関連化合物ライブラリー	Kinase Inhibitor Library PI3K/Akt Inhibitor Library MAPK Inhibitor Library DNA Damage/DNA Repair compound Library Cell Cycle compound library	もっと見る

シグナル伝達経路

Rasシグナル伝達経路

Ras阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	活性情報	PMID
J774A.1	Antiproliferative assay	100 uM	72 hrs	Antiproliferative activity against mouse J774A.1 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay	30216851
RAW264.7	Antiproliferative assay	100 uM	72 hrs	Antiproliferative activity against mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay	30216851
MG63	Antiproliferative assay	100 uM	72 hrs	Antiproliferative activity against human MG63 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay	30216851
PC3	Antiproliferative assay	100 uM	72 hrs	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability at 100 uM after 72 hrs by WST8 assay	30216851
RAW264.7	Antiproliferative assay	100 uM	72 hrs	Antiproliferative activity against RANKL-differentiated mouse RAW264.7 cells assessed as reduction in cell viability at 100 uM after 72 hrs by CCK8 assay	30216851
MC3T3-E1	Function assay	30 to 50 nM	10 to 15 days	Induction of mineralization in mouse MC3T3-E1 cells at 30 to 50 nM after 10 to 15 days by alizarin red dye based assay	30216851
C57BL mouse bone marrow cells	Function assay	50 nM	10 to 15 days	Induction of mineralization in C57BL mouse bone marrow cells at 50 nM supplemented with fresh medium containing compound every 3 days for 10 to 15 days by alizarin red dye based assay	30216851
C57BL mouse bone marrow cells/human PC3 cells	Function assay	50 to 100 nM	10 to 15 days	Induction of mineralization in C57BL mouse bone marrow cells co-cultured with human PC3 cells at 50 to 100 nM supplemented with fresh medium containing compound every 3 days for 10 to 15 days by alizarin red dye based assay	30216851
RPMI8226	Function assay	0.5 uM		Inhibition of GGPPS in human RPMI8226 cells assessed as reduction in Rap1A prenylation at 0.5 uM by Western blot analysis	30016091
BL21(DE3)	Function assay		30 mins	Inhibition of His6-tagged human truncated FPPS (6-353) expressed in Escherichia coli BL21(DE3) cells using geranyl diphosphate and isopentenyl diphosphate as substrate preincubated with enzyme for 30 mins by spectrophotometric analysis, IC50=0.1μM	23610597
BL2-codon plus (DE3) RIL	Function assay		30 mins	Inhibition of N-terminal His6-tagged Plasmodium vivax GGPPS expressed in Escherichia coli BL2-codon plus (DE3) RIL cells using geranyl diphosphate and isopentenyl diphosphate as substrate preincubated with enzyme for 30 mins by spectrophotometric analysis, IC50=0.13μM	23610597
RPMI8226	Cytotoxicity assay		72 hrs	Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay, EC50=11μM	23998921
MCF7	Antiproliferative assay		72 hrs	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50=23μM	24928399
Vgamma9/Vdelta2 T-cells	Function assay		18 hrs	Binding affinity to butyrophilin 3A1 in human Vgamma9/Vdelta2 T-cells assessed as activation of Vgamma9/Vdelta2 T-cells by upregulation of CD69 and CD25 after 18 hrs, EC50=0.4866μM	29457898
RPMI8226	Antiproliferative assay		72 hrs	Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay, EC50=11μM	30016091
RAW264.7	Function assay		72 hrs	Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells after 72 hrs by TRAP staining based microscopic analysis	30216851
K562	Function assay		240 mins	Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 240 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA, EC50=23μM	31531198
MIAPaCa2	Cytotoxicity assay		72 hrs	Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay, EC50=13.4μM	31725297
PANC1	Cytotoxicity assay		72 hrs	Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay, EC50=16.1μM	31725297
HFF cells	Function assay			Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.60 uM, experiment 1), IC50=7.8μM	15857119
HFF cells	Function assay			In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells), IC50=0.79μM	15857119
Gamma delta T cells	Function assay			Effective concentration against human Gamma delta T cells, EC50=5.4μM	15828834
human SF-268 cell	Proliferation assay			Antiproliferative activity against human SF-268 cell line by MTT assay, IC50=14.3 μM	16970405
human NCI-H460 cell	Proliferation assay			Antiproliferative activity against human NCI-H460 cell line by MTT assay, IC50=11.7 μM	16970405
HFF cells	Function assay			Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.79 uM, experiment 3), IC50=7.8μM	15857119
HFF cells	Function assay			Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 1.1 uM, experiment 2), IC50=8.3μM	15857119
BT-549	Antitumor assay			Antitumor activity against human BT-549 cells xenografted SCID mouse co-transfected with human gamma delta T lymphocytes assessed as survival time prolongation at 2 ug, ip coadministered with human recombinant IL2	18937434
BT-549	Antitumor assay			Antitumor activity against human BT-549 cells xenografted SCID mouse co-transfected with human gamma delta T lymphocytes assessed as survival time prolongation at 5 ug, ip coadministered with human recombinant IL2	18937434
J774	Cytotoxicity assay			Cytotoxicity against mouse J774 cells assessed as reduction in cell viability, IC50=7.8μM	24813742
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Targets

Rho ^[1]
(Cell-free assay)

Ras ^[1]

In Vitro
In vitro	Zoledronic acid (10 µM and 100 µM) causes a significant reduction in the proportions of MCF-7 cells (49.54% and 23.55% of control, respectively) (P < 0.05). Zoledronic acid has little effect on MDA-MB-231 cells at concentrations of 0.1–10 µM, whereas the 100 µM concentration results in a significant reduction in cell number. Zoledronic acid (100 µM) results in a 63.5% reduction in MCF-7 cell number at 72 hours and an 87.1% reduction at 96 hours. Zoledronic acid (10 µM) results in a greater than 4-fold increase in MCF-7 cell apoptosis whereas the 100 µM concentration induces a 6-fold increase in the proportion of apoptotic cells. Zoledronic acid (10 µM) and paclitaxel (2 µM) results in a 5-fold increase in apoptosis (774.8% of control) compared to zoledronic acid alone (155.71%) and a 4-fold increase compared to paclitaxel alone (189.68%). Zoledronic acid-induced apoptosis of MCF-7 breast cancer cells can be inhibited by addition of intermediates of the mevalonate pathway, which is consistent with observations in osteoclasts, macrophages and myeloma cells. ^[1] Zoledronic acid enhances OPG gene expression and protein secretion by human osteoblasts (hOB) in a dose-dependent fashion with a maximum effect at 10 nM after 72 hours, consistent with the higher biological potency of Zoledronic acid. Zoledronic acid prevents the inhibitory effects of the glucocorticoid dexamethasone on OPG mRNA and protein production in human osteoblasts. Zoledronic acid induces type I collagen secretion and alkaline phosphatase activity by 2- and 4-fold, respectively, in human osteoblasts. ^[2]
細胞実験	細胞株	MCF7 cells
	濃度	100 μM
	反応時間	72 h
	実験の流れ	Cells were treated with various concentrations of drug for 72 h.
実験結果図	Methods	Biomarkers	結果図	PMID
	Western blot	ALDH1 / Oct4 / Nanog / Sox2 / CD49f N-cadherin / E-cadherin / Vimentin		30791957
	Growth inhibition assay	Cell viability		30791957

In Vivo
In Vivo	Zoledronic acid (120 ug/kg, s.c.) prevents the formation of lesions, prevents cancellous bone loss and loss of bone mineral density, and reduces osteoclast perimeter in 5T2MM-bearing mice. Zoledronic acid (120 mg/kg, s.c.) also decreases paraprotein concentration, decreases tumor burden, and reduces angiogenesis in 5T2MM-bearing mice. ^[3]
動物実験	動物モデル	Male C57BL/KaLwRij mice
	投与量	120 µg/kg
	投与経路	s.c.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06217718	Not yet recruiting	Copd\|Empowerment\|Empowerment Patient\|Self Efficacy	Zahide Aksoy\|The Scientific and Technological Research Council of Turkey\|Marmara University	February 15 2024	Not Applicable
NCT05743179	Recruiting	Hip Fractures\|Pneumonia	The University of Hong Kong\|Queen Mary Hospital Hong Kong\|Caritas Medical Centre Hong Kong\|Prince of Wales Hospital Shatin Hong Kong\|United Christian Hospital	December 5 2022	Phase 4
NCT02864784	Withdrawn	Castrate Resistant Prostate Cancer With Bone Metastasis	Amorphical Ltd.	June 2022	Phase 1
NCT04957641	Completed	Hereditary Angioedema	Takeda	April 21 2022	--
NCT05213286	Unknown status	Autism Spectrum Disorder\|Schizotypal Disorder	Glostrup University Hospital Copenhagen	February 1 2022	Not Applicable

参考
[1] Jagdev SP, et al. Br J Cancer, 2001, 84(8), 1126-1134. [2] Viereck V, et al. Biochem Biophys Res Commun, 2002, 291(3), 680-686. [3] Croucher PI, et al. J Bone Miner Res, 2003, 18(3), 482-492.

参考

化学情報

分子量	272.09	化学式	C₅H₁₀N₂O₇P₂
CAS No.	118072-93-8	SDF	Download Zoledronic acid (Zoledronate) SDFをダウンロードする
Smiles	C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

0.1M NAOH : 25 mg/mL (Ultrasonic and heating for 5 minutes.)

Water : 0.5 mg/mL (Warmed with 50℃ water bath; Ultrasonicated)

DMSO : Insoluble ( 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

よくある質問（FAQ）

質問1:
How can I reconstitute the compound for in vivo studies?

回答
Please dissolve this compound directly to 30% PEG400+0.5% Tween80+5% Propylene glycol.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):